Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens.
AIDS Patient Care STDS
; 29(6): 329-37, 2015 Jun.
Article
em En
| MEDLINE
| ID: mdl-26020726
ABSTRACT
Hepatitis C (HCV)-related liver disease has become one of the leading causes of death in HIV patients. With the development of new direct-acting antivirals for HCV, treatment regimens have become shorter, more effective, and easier to tolerate without interferon. However, cost may be a significant impediment to the widespread use of these newer agents in both resource-rich and resource-poor settings. In HIV patients, treatment for HCV is not always as straightforward compared with HCV monoinfected patients due to potential drug-drug interactions. In this article, we will examine by genotypes the FDA approved direct-acting antivirals, as well as those in clinical trials that will soon be FDA-approved focusing on data in HCV/HIV co-infection. Preferred agents for HCV treatment and potential drug-drug interactions with antiretroviral therapy (ART) will be highlighted.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Infecções por HIV
/
Hepatite C
/
Hepacivirus
/
Coinfecção
Limite:
Humans
Idioma:
En
Revista:
AIDS Patient Care STDS
Assunto da revista:
DOENCAS SEXUALMENTE TRANSMISSIVEIS
/
SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS)
Ano de publicação:
2015
Tipo de documento:
Article